439 related articles for article (PubMed ID: 30293943)
1. Resistance to molecularly targeted therapy in non-small-cell lung cancer.
Asao T; Takahashi F; Takahashi K
Respir Investig; 2019 Jan; 57(1):20-26. PubMed ID: 30293943
[TBL] [Abstract][Full Text] [Related]
2. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
Ke L; Xu M; Jiang X; Sun X
Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
[TBL] [Abstract][Full Text] [Related]
3. Resistance Mechanisms to Targeted Therapies in
McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
[No Abstract] [Full Text] [Related]
4. Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers.
Tan AC; Itchins M; Khasraw M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093103
[TBL] [Abstract][Full Text] [Related]
5. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y
Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279
[TBL] [Abstract][Full Text] [Related]
6. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y
BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926
[TBL] [Abstract][Full Text] [Related]
7. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
Remon J; Hendriks LE; Cabrera C; Reguart N; Besse B
Cancer Treat Rev; 2018 Dec; 71():47-58. PubMed ID: 30359792
[TBL] [Abstract][Full Text] [Related]
9. Novel targets in non-small cell lung cancer: ROS1 and RET fusions.
Gainor JF; Shaw AT
Oncologist; 2013; 18(7):865-75. PubMed ID: 23814043
[TBL] [Abstract][Full Text] [Related]
10. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations.
Wang H; Wang Z; Zhang G; Zhang M; Zhang X; Li H; Zheng X; Ma Z
Cancer Med; 2020 Jan; 9(2):487-495. PubMed ID: 31769228
[TBL] [Abstract][Full Text] [Related]
11. VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.
Watanabe H; Ichihara E; Kayatani H; Makimoto G; Ninomiya K; Nishii K; Higo H; Ando C; Okawa S; Nakasuka T; Kano H; Hara N; Hirabae A; Kato Y; Ninomiya T; Kubo T; Rai K; Ohashi K; Hotta K; Tabata M; Maeda Y; Kiura K
Cancer Sci; 2021 May; 112(5):1853-1864. PubMed ID: 33410241
[TBL] [Abstract][Full Text] [Related]
12. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].
Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155
[No Abstract] [Full Text] [Related]
13. Treatment of oncogene-driven non-small cell lung cancer.
Kastelijn EA; de Langen AJ; Peters BJM
Curr Opin Pulm Med; 2019 May; 25(3):300-307. PubMed ID: 30865033
[TBL] [Abstract][Full Text] [Related]
14. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
15. [Research Progress of Acquired Resistance Mediated by MET Amplification
in Advanced Non-small Cell Lung Cancer].
Pan S; Wang N; Song X
Zhongguo Fei Ai Za Zhi; 2022 Aug; 25(8):615-621. PubMed ID: 36002199
[TBL] [Abstract][Full Text] [Related]
16. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
Chen LF; Chen XY; Yu XB
Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
[TBL] [Abstract][Full Text] [Related]
17. Expression and copy number gains of the RET gene in 631 early and mid stage non-small cell lung cancer cases.
Tan L; Hu Y; Tao Y; Wang B; Xiao J; Tang Z; Lu T; Tang H
Thorac Cancer; 2018 Apr; 9(4):445-451. PubMed ID: 29473341
[TBL] [Abstract][Full Text] [Related]
18. Correlation between combining
Ruan M; Liu L; Wang L; Lei B; Sun X; Chang C; Shen Y; Xie W
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1183-1197. PubMed ID: 31897590
[TBL] [Abstract][Full Text] [Related]
19. ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy.
Rosell R; Karachaliou N; Wolf J; Ou SH
Lancet Respir Med; 2014 Dec; 2(12):966-8. PubMed ID: 25466349
[No Abstract] [Full Text] [Related]
20. Gene rearrangement detection by next-generation sequencing in patients with non-small cell lung carcinoma.
Brisudova A; Skarda J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Jun; 164(2):127-132. PubMed ID: 32284620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]